FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Nicole Denis

Research Profile

Disorders

Living Beings

Anatomy

Chemicals & Drugs

Physiology

Co-author Network

Publications

TOP 3
Dorothée Buet; Nicole Denis; Isabelle Dusanter-Fourt; Isabelle Gallais; francois guillonneau; Christel Guillouf; Olivier Kosmider; Evelyne Lauret; Damarys Loew; Bérangère Lombard; Patrick Mayeux; Françoise Moreau-Gachelin
Cotargeting signaling pathways driving survival and cell cycle circumvents resistance to Kit inhibitors in leukemia.
Dorothée Selimoglu-Buet; Nicole Denis; Isabelle Gallais; Christel Guillouf; Françoise Moreau-Gachelin
Oncogenic kit triggers Shp2/Erk1/2 pathway to down-regulate the pro-apoptotic protein Bim and to promote apoptosis resistance in leukemic cells.
Olivier Kosmider; Nicole Denis; P Dubreuil; Françoise Moreau-Gachelin
Semaxinib (SU5416) as a therapeutic agent targeting oncogenic Kit mutants resistant to imatinib mesylate.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Nicole Denis (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Dorothée Buet; Nicole Denis; Isabelle Dusanter-Fourt; Isabelle Gallais; francois guillonneau; Christel Guillouf; Olivier Kosmider; Evelyne Lauret; Damarys Loew; Bérangère Lombard; Patrick Mayeux; Françoise Moreau-Gachelin
Cotargeting signaling pathways driving survival and cell cycle circumvents resistance to Kit inhibitors in leukemia.
Blood 2012;119(18):4228-41.
2012: Dorothée Selimoglu-Buet; Nicole Denis; Isabelle Gallais; Christel Guillouf; Françoise Moreau-Gachelin
Oncogenic kit triggers Shp2/Erk1/2 pathway to down-regulate the pro-apoptotic protein Bim and to promote apoptosis resistance in leukemic cells.
PloS one 2012;7(11):e49052.
2007: Olivier Kosmider; Nicole Denis; P Dubreuil; Françoise Moreau-Gachelin
Semaxinib (SU5416) as a therapeutic agent targeting oncogenic Kit mutants resistant to imatinib mesylate.
Oncogene 2007;26(26):3904-8.
2006: Stéphane Barnache; Erwan Le Scolan; Olivier Kosmider; Nicole Denis; Françoise Moreau-Gachelin
Phosphatidylinositol 4-phosphatase type II is an erythropoietin-responsive gene.
Oncogene 2006;25(9):1420-3.
2005: Olivier Kosmider; Nicole Denis; Catherine Lacout; William Vainchenker; Patrice Dubreuil; Françoise Moreau-Gachelin
Kit-activating mutations cooperate with Spi-1/PU.1 overexpression to promote tumorigenic progression during erythroleukemia in mice.
Cancer cell 2005;8(6):467-78.
2005: Erwan Le Scolan; Dimitri Pchejetski; Yoshiko Banno; Nicole Denis; Patrick Mayeux; William Vainchenker; Thierry Levade; Françoise Moreau-Gachelin
Overexpression of sphingosine kinase 1 is an oncogenic event in erythroleukemic progression.
Blood 2005;106(5):1808-16.
2004: Laurent Delva; Isabelle Gallais; Christel Guillouf; Nicole Denis; Christophe Orvain; Françoise Moreau-Gachelin
Multiple functional domains of the oncoproteins Spi-1/PU.1 and TLS are involved in their opposite splicing effects in erythroleukemic cells.
Oncogene 2004;23(25):4389-99.
2001: E L Scolan; Françoise Wendling; Stéphane Barnache; Nicole Denis; Micheline Tulliez; William Vainchenker; Françoise Moreau-Gachelin
Germ-line deletion of p53 reveals a multistage tumor progression in spi-1/PU.1 transgenic proerythroblasts.
Oncogene 2001;20(39):5484-92.
1998: Stéphane Barnache; Françoise Wendling; C Lacombe; Nicole Denis; Monique Titeux; William Vainchenker; Françoise Moreau-Gachelin
Spi-1 transgenic mice develop a clonal erythroleukemia which does not depend on p53 mutation.
Oncogene 1998;16(23):2989-95.